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Preoperative characterization of thyroid follicular lesions is challenging. Fine-needle aspiration specimens cannot
differentiate follicular carcinomas from benign follicular neoplasias. Recently, promising markers have been
detected using modern molecular techniques. We conducted a retrospective study to confirm the usefulness of
immunohistochemical staining for the protein markers, DDIT3, STT3A (ITM1), ARG2 and FAM129A (C1orf24) in
separating benign and malignant thyroid follicular lesions. Formalin-fixed, paraffin-embedded thyroid tissue from
30 in-house cases (15 follicular carcinomas and 15 follicular adenomas), as well as 8 follicular carcinomas and 21
follicular adenomas on tissue microarray slides were stained immunohistochemically for DDIT3, STT3A, ARG2
and FAM129A expression. Control tissue consisted of thyroid parenchyma adjacent to the tumors and 11 separate
cases of normal thyroid parenchyma. All in-house cases of follicular adenomas, follicular carcinomas and
adjacent normal thyroid tissue showed positive immunostaining with anti-DDIT3 and anti-STT3A. Anti-ARG2 and
anti-FAM129A polyclonal antibodies showed positive staining in 20 and 60% of in-house follicular adenomas, and
40 and 87% of in-house follicular carcinomas, respectively. Monoclonal anti-FAM129A demonstrated positive
staining in 13 and 33% of in-house follicular adenomas and follicular carcinomas, respectively. Polyclonal anti-
DDIT3, -STT3A and -FAM129A antibodies showed positive staining in all tissue microarray slides of follicular
carcinoma and in 76, 85 and 81% of the follicular adenomas, respectively. Monoclonal anti-STT3A stained 81% of
the follicular adenoma cores. Anti-ARG2 stained positive in 13% of follicular carcinomas and 10% of follicular
adenomas on the tissue microarray slides. In conclusion, DDIT3, STT3A, ARG2 and FAM129A immunohis-
tochemistry does not appear to be useful in the diagnosis of thyroid follicular neoplasias, as they do not reliably
distinguish follicular thyroid carcinoma from follicular thyroid adenoma.
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Fine-needle aspiration biopsy has become the most
widely used preoperative method to diagnose
thyroid nodules.
1–3 Since it’s introduction in Europe
in the 1970s, and in the US some years later, there
has been a dramatic reduction in the need for
diagnostic hemi-thyroidectomies, whereas the yield
of thyroid carcinomas has increased.
4 For papillary
carcinomas, cytology smears usually are sufficient to
make a diagnosis, due to the presence of cells with
nuclei characteristic for papillary carcinoma. In
marked contrast, in follicular neoplasias, cytological
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benign follicular adenomas and malignant folli-
cular carcinomas.
5–10 Indeed, a definite diagnosis
of follicular carcinoma requires surgical excision for
histological characterization and the examination of
multiple paraffin sections for evidence of capsular
or vascular invasion. The reported rate of malig-
nancy in follicular-patterned lesions diagnosed as
either atypical or indeterminate ranges between 20
and 30%,
5,8,11–22 and many patients are operated
upon unnecessarily. The cost of these procedures is
high, both economically and in patient morbidity.
Recently, a number of promising molecular
and immunohistochemical methods have been
described, which could improve the diagnostic
accuracy of fine-needle aspiration biopsy.
23–29 How-
ever, there is some inter-laboratory variability in
the sensitivity and specificities obtained with the
individual techniques as shown in the review by
Griffith et al.
30 Significantly, none of the methods
has been fully validated to the extent that it is in
general use in the routine diagnostic laboratory.
In 2006, Cerutti et al
31 described a test that could
discriminate between follicular carcinoma and
follicular adenoma on both paraffin sections and
cytology preparations. Their original immunohisto-
chemical method was based on the selective stain-
ing of follicular carcinoma cells by antibodies
reactive to four protein markers: DDIT3 (also known
as CHOP and GADD153), STT3A (also known as
ITM1), ARG2 and FAM129A (also known as C1orf24
and Niban). Overexpression of these proteins was
first observed using serial analysis of gene expres-
sion procedures on a single follicular carcinoma
specimen and subsequently confirmed using quan-
titative reverse-transcription PCR. The four proteins
have diverse cellular functions including nitric
oxide and polyamine metabolism (ARG2), regula-
tion of protein translation (FAM129A), regulation
of transcription as CCAAT/enhancer-binding trans-
cription factor (DDIT3), and as component of the
N-oligosaccharide transfer enzyme (STT3A). Cerutti
et al
31,32 found, by using immunohistochemistry,
that the combination of the four markers distin-
guished a variety of thyroid tumors commonly
classified as indeterminate on fine-needle aspiration
biopsy, with an estimated sensitivity of 100% and
specificity of 85% for detecting malignancy.
The aim of this study was to verify the predictive
accuracy of the new biomarkers DDIT3, STT3A,
ARG2 and FAM129A in distinguishing follicular
carcinoma from follicular adenoma.
Materials and methods
Tissue Sections
Formalin-fixed, paraffin-embedded thyroid tissue
blocks were retrieved from the archive maintained
at the Department of Pathology, The Norwegian
Radium Hospital. A total of 30 cases, consisting of
15 follicular carcinomas and 15 follicular adenomas,
originally submitted for diagnostic purposes,
were included. The in-house cases have been
diagnosed histopathologically according to World
Health Organization criteria.
33 Follicular neoplasias
with oncocytic differentiation, and areas containing
cells demonstrating oncocytic differentiation, were
excluded from the evaluation. In all cases, hemat-
oxylin and eosin-stained slides were reviewed to
confirm the original histopathological diagnosis.
Before embedding, the tissue specimens had been
preserved in 4% buffered formalin for variable
periods, but within the range of 2–5 days.
Two tissue microarrays containing either 80
samples from normal thyroid parenchyma (serial
TH804) or 80 thyroid cases with pathological
findings, including 8 follicular carcinomas and 21
follicular adenomas (serial TH802), were purchased
from US Biomax (Rockville, USA). The product
supplier stated that the tissues used to construct
these arrays had been preserved in neutral phos-
phate-buffered formalin for a maximum of 24h
before embedding.
Antibody Preparation
Rabbit polyclonal antisera to FAM129A (C1orf24)
and STT3A (ITM1) were generated using C-terminal
peptides as described by Cerutti et al.
31 The pep-
tides were custom-synthesized and conjugated to
diphtheria toxoid (Mimotopes, Clayton, VIC, Aus-
tralia). Immunizations were performed using the
diphtheria toxoid conjugates by Eurogentec (Lie `ge,
Belgium). Monoclonal antibodies were produced by
fusion of NS0 myeloma cells with splenocytes from
BALB/c mice immunized with peptide–diphtheria
toxoid conjugates.
Antibody titration and hybridoma screening were
performed using antibody capture assays with bio-
tinylated peptides presented on streptavidin-coated
microplates (Wallac Oy, Turku, Finland). Specificity
was established using ELISA, western blotting and
125I-peptide displacement assays.
Polyclonal rabbit anti-GADD 153 (DDIT3; sc-793)
and anti-Arginase-2 (sc-20151) were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Experimental animals were handled in accor-
dance with national and institutional guidelines.
125I-Peptide Displacement Assays
Competitive immunoassay tracers were produced by
incubating biotinylated peptides with an excess of
125I-labeled streptavidin. Iodination was performed
with the indirect Iodogen-method (Pierce, Rockford,
IL, USA). The test was performed by incubating
tracer and antisera (dilution 1:10000) for 3h in
the presence and absence of tissue homogenate.
Antibody/antigen complexes were then isolated by
the addition of sheep anti-immunoglobulin-coated
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The suspension was incubated for 1h with shaking,
washed three times and bound tracer counted in a
g-counter.
Western Blotting
Tissue samples or cells from a follicular carcinoma
line, FTC-133 (EACC, Salisbury, UK) were homo-
genized in ice-cold RIPA buffer (TBS, 1% NP-40,
0.25% sodium deoxycholate, 0.1% SDS) containing
5mM EDTA, 1mM phenylmethylsulfonylfluoride,
0.2mM aprotinin, 1mM leupeptin and 1mMp e p -
statin A. Following clarification, soluble protein
concentrations were determined using the BCA
method (Pierce). Between 20 and 40mg/lane of total
protein was subjected to SDS-PAGE (Invitrogen;
Novex 4–12% gradient) and subsequently trans-
ferred onto nitrocellulose. The membranes were
blocked with 5% skimmed milk/TBS, followed by
incubation for 1h with the monoclonal (1:10 dilu-
tion of culture supernatant) or polyclonal (1:2000–
1:5000) antibodies diluted in 5% milk/TBS. Loading
controls were stained for GAPDH and a-tubulin.
Detection utilized HRP-labeled goat anti-species
immunoglobulin (1:6000 dilution poly-HRP, Pierce)
and the SuperSignal West Pico chemiluminescent
substrate (Pierce).
Immunohistochemical Staining
Immunohistochemistry was performed on 3mm
paraffin sections mounted on positively charged
slides, essentially as described by Cerutti et al.
31
Tissue sections were dewaxed in xylene, followed
by rehydration using a graded ethanol series.
Endogenous peroxidase activity was suppressed by
pretreatment with 0.03% hydrogen peroxide, and
antigen retrieval was achieved using buffer AR-10
(Biogenex, San Ramon, CA, USA) in a steamer for
10min. Immunodetection was undertaken using a
Dako automated tissue-staining system (S3400;
Dako, Carpinteria, CA, USA), using EnVisionþ
HRP reagents (K4007 and K4011, Dako). Tissue
sections were exposed to the primary antibodies
for 20–22h at 41C. The optimal dilution of each
antibody was determined in preliminary staining
trials. Appropriate controls were prepared using
(1) non-immune polyclonal rabbit antisera or mouse
IgG1 myeloma immunoglobulin and (2) anti-
FAM129A and anti-STT3A, preabsorbed with
1mg/ml FAM129A antigen and 1mg/ml STT3A
antigen, respectively.
Two independent surgical pathologists (ES and
AaB) performed the slide evaluation. Tissue sections
were assigned to one of four groups, based on
the proportion of cells showing unequivocal stain-
ing: 0, (0%); 1, (o25%); 2, (25–50%); 3, (51–75%); 4,
(475%). The scoring system used a cutoff for
positive staining of 425%, which is in accordance
with accepted scoring methods. Arginase-2 and
STT3A staining was detected primarily in the
cytoplasm of the follicular cells, FAM129A in the
cytoplasmic membrane and the cytoplasm, whereas
DDIT3 expression was observed both in the nucleus
and the cytoplasm. For each of the in-house cases,
staining of the normal thyroid tissue adjacent to the
tumor was also evaluated. The inter-observer agree-
ment was 94% for the in-house cases and 83% for
the tissue microarray slides. Discordant cases were
reevaluated using a multi-headed microscope to
obtain a consensus. Images displayed in this article
were captured using a Leica DMLB microscope
(Type 020-519.511DMLB 100T; Leica Microsystems
GmbH, Germany) equipped with a Nikon digital
Sight DS-Fi1 camera (Nikon Corporation, Japan),
and processed using JASC Paint Shop Pro software
(Version 7.02, Corel Corporation, USA).
Statistics
The data were analyzed using the Statistical Pack-
age for the Social Sciences (SPSS), version 17.0.1
for Windows (SPSS, Chicago, IL, USA). The
Mann–Whitney U-test was used to determine
DDIT3, STT3A, ARG2 and FAM129A expression
level differences between follicular adenomas and
follicular carcinomas. A P-value of o0.05 was
considered statistically significant. Sensitivity and
specificity were calculated using standard formulae
for each of the antibodies individually, using benign
versus malignant histological diagnosis as the
standard.
Ethics
The study was approved by the Regional Committee
for Medical Research Ethics and the ‘Personvernom-
budet’ at Rikshospitalet. Informed consent for the
use of material was obtained from the patients.
Results
Production and Characterization of Antibodies
Antibodies to STT3A and FAM129A are not com-
mercially available and were produced in-house.
Rabbits were hyper-immunized with the appropriate
C-terminal peptide and antibody titers followed
by antibody-capture ELISA. After one primary
injection and three booster doses, antisera with
titers 41:10000 were obtained. The sera were
screened by radioimmunoassay displacement ana-
lysis using follicular carcinoma, follicular adenoma
and normal tissue lysates. Sera that demonstrated
more efficient peptide displacement with follicular
carcinoma lysates compared with follicular adeno-
ma or normal cell extracts were selected (data not
shown). The specificity of the anti-FAM129A
and anti-STT3A antibodies determined by western
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detected proteins with the expected molecular
weight of approximately 130 and 60kDa, respec-
tively (Figure 1).
Monoclonal antibodies were also generated using
splenocytes from mice immunized with the peptide
conjugates. Approximately, 1000 parental hybrido-
mas/peptide were screened for reactivity by anti-
body-capture assay using biotinylated peptides.
Secondary screening was undertaken by immuno-
cytochemistry using the FTC-133 cell line. Two
hybridomas were selected, producing antibodies to
FAM129A (clone E253) and STT3A (clone E239).
The specificity of the anti-FAM129A and anti-
STT3A was determined by preabsorption of the
antiserum with blocking peptides. Absorbed poly-
clonal and monoclonal anti-FAM129A antibodies
and the monoclonal anti-STT3A antibody gave
negative immunostaining. A faint immunoreaction
was observed with preabsorbed polyclonal anti-
STT3A antibody (data not shown). However, this
background was easily distinguishable from a
positive staining reaction.
Immunohistochemistry
Paraffin sections from 30 in-house cases were
screened for the expression of DDIT3, STT3A,
ARG2 and FAM129A, using a panel of polyclonal
and monoclonal antibodies (Figure 2a). Positive
staining for anti-DDIT3 and anti-STT3A was
observed in all the cases of follicular carcinoma
and follicular adenoma. The normal tissue adjacent
to the tumors was also stained. Comparable binding
was obtained with polyclonal or monoclonal anti-
STT3A antibodies. ARG2 was detected in 40% of
follicular carcinoma cases, 20% of the follicular
Figure 1 Specificity of the anti-FAM129A and anti-STT3A
antibodies as determined by western blotting. Total cell lysates
of the FTC-133 cell line were subjected to SDS-PAGE using 4–
12% gradient gels. After transfer, the nitrocellulose membranes
were stained with the primary antibody followed by a HRP-goat
anti-rabbit secondary reagent. Detection utilized a chemolumi-
nescent substrate.
Figure 2 Frequency of binding of the four antibodies to follicular
adenoma, follicular carcinoma and adjacent normal thyroid tissue
in in-house cases (a), and in follicular adenoma, follicular
carcinoma and separate cases of normal thyroid tissue in tissue
microarray cases (b). FTA¼follicular thyroid adenoma, FTC¼fol-
licular thyroid carcinoma, N¼normal thyroid tissue.
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adjacent to the tumors. The polyclonal antibody
to FAM129A demonstrated positive staining of
follicular cells in 87% of the follicular carcinoma
cases, 60% of the follicular adenomas and 72% of
the adjacent normal tissues. In contrast, the anti-
FAM129A monoclonal antibody stained 33% of
follicular carcinoma cases, and 13% of both the
follicular adenomas and the adjacent normal tissues.
The immunohistochemical staining with the four
antibodies of in-house follicular adenoma and
follicular carcinoma cases, and the adjacent non-
neoplastic thyroid tissue and two negative controls
is shown in Figure 3. The observed staining of
normal tissue was not due to leaking from the
adjacent follicular adenoma or follicular carcinoma,
as we found antibody binding in a panel of 11
thyroid specimens that displayed normal morpho-
logy. With this normal tissue panel, binding of
the polyclonal DDIT3, STT3A and ARG2 antibodies
was seen in all 11 individuals. Staining with the
FAM129A polyclonal antibody was found in nine
cases, whereas the monoclonal anti-FAM129A and
anti-STT3A stained seven and nine cases, respec-
tively.
In preliminary trials, we tried to ameliorate what
we thought was the ‘artifactual’ staining of follicular
adenoma and normal thyroid parenchyma, using a
range of techniques. These included alternative
antigen-retrieval buffers (citrate, Tris-Cl, citraconic
anhydride), peroxidase blocking (H2O2,H 2O2/
methanol, H2O2/sodium azide), protein blocking
reagent (normal serum, casein, fish gelatine, differ-
ent BSA batches) and pre-treatment of the primary
antibodies with thiol reagents. In each case, we
failed to block the staining of follicular adenoma
and normal thyroid epithelium (data not shown).
On the tissue microarray slides (Figure 2b),
expression of DDIT3, STT3A and FAM129A was
found in all the follicular carcinoma tissue cores and
in 76, 85 and 81% follicular adenoma cores, respec-
tively. Only 13% follicular carcinoma samples and
10% of the follicular adenoma cores showed
positive staining with anti-ARG2. The tissue micro-
array slides containing normal thyroid tissue (which
did not originate from the same individuals as the
tumor cases) showed positive staining in 30, 63 and
29%, of the cores with polyclonal anti-DDIT3,
-STT3A and -FAM129A, respectively. Expression
of ARG2 was detectable in only 1% of individuals.
The monoclonal antibody to STT3A stained 46% of
the tissue cores. Immunostaining with the four
antibodies of tissue microarray cores from follicular
adenoma and follicular carcinoma cases, and sepa-
rate tissue microarray cores from normal thyroid
tissue is shown in Figure 4.
Mann–Whitney test was performed on the scoring
data from both in-house slides and tissue microarray
slides. The evaluation of difference in sum of ranks
between follicular carcinoma and follicular adeno-
ma cases revealed no significant P-values for the
in-house cases, and for the tissue microarray cases, a
P-value of 0.04 for DDIT3, and a non-significant
value for STT3A polyclonal of P¼0.37, for STT3A-
monoclonal of P¼0.24, for ARG2 of P¼0.28 and for
FAM129A of P¼0.08. Defining sensitivity as the
proportion of follicular carcinoma patients who
expressed a marker, and specificity as the propor-
tion of patients with follicular adenoma, who did
not express the marker,
31 the sensitivity and speci-
ficity of staining with each of the antibodies were
calculated, and a summary of the calculated sensi-
tivity and specificity of staining with each of the
antibodies for the in-house and tissue microarray
slides is shown in Table 1a and b, respectively.
Tissue Distribution of DDIT3, STT3A, ARG2 and
FAM129A by Western Blotting
The results from immunoblotting studies are shown
in Figure 5. Tissue extracts from two carcinomas and
five adenomas were used. For one follicular carci-
noma (lane 2) and one follicular adenoma (lane 5),
tissue extracts from the non-involved lobe were also
available for testing (sample lane 3 and lane 4,
respectively). Our polyclonal and monoclonal anti-
bodies to STT3A showed high specificity and
detected a protein with the expected molecular
weight of approximately 60kDa. Immunoblots per-
formed using the polyclonal anti-STT3A or the
corresponding monoclonal antibody showed good
concordance. With both reagents, STT3A protein
was found in all follicular carcinoma cases and in
three out of five of the follicular adenoma tissue
lysates. Low, but detectable STT3A expression was
also found in normal thyroid tissue. The polyclonal
anti-FAM129A was highly specific, detecting a
protein with an apparent Mw of about 130kDa.
FAM129A was highly expressed in one of the
follicular carcinoma lysates, four out of five folli-
cular adenoma cases and one normal tissue extract.
In contrast to the anti-STT3A monoclonal antibody,
the anti-FAM129A monoclonal antibody performed
very poorly in western blotting and was not
characterized (data not shown). The commercial
anti-ARG2 reacted with a protein of 40kDa with
good specificity. The protein was highly expressed
in both follicular carcinomas and three out of five
follicular adenoma lysates. Low levels of ARG2
were found in all the tissue samples. Surprisingly,
the commercial anti-DDIT3 proved highly non-
specific, showing binding to many proteins within
the 50–200kDa range. This antibody did, however,
detect a 30kDa protein, presumably mature DDIT3,
in one of the follicular carcinoma, but none of the
follicular adenoma tumor lysates.
Discussion
Fine-needle aspiration biopsy of the thyroid is
the most commonly used preoperative method to
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Modern Pathology (2012) 25, 537–547Figure 3 Immunohistochemical detection of DDIT3, STT3A, ARG2 and FAM129A in follicular adenoma and the adjacent normal thyroid
tissue (a–d;  50) and follicular carcinoma and the adjacent normal thyroid tissue (f–i;  50) in in-house cases. Negative controls are
shown in panels e and j.F T A¼follicular thyroid adenoma, FTC¼follicular thyroid carcinoma, N¼normal thyroid tissue.
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aspiration biopsy can reduce the number of diag-
nostic thyroidectomies by identifying clearly benign
lesions, it cannot reliably distinguish between
follicular adenoma and follicular carcinoma.
Many authors have attempted to identify molecular
markers able to predict follicular carcinoma, but
with conflicting results.
30 The discordances may be
a result of the biased selection of material, the
limited number of cases examined, or the use of
very different molecular and immunohistochemical
methods. Among the most promising markers in the
recent literature are DDIT3, STT3A, ARG2 and
FAM129A that, according to Cerutti et al,
31,32
reliably identify follicular carcinoma. However, the
utility of these markers has not been confirmed by
other laboratories, and they are not widely used in
diagnostic practice.
In this study, we tested the ability of immunohis-
tochemical staining for DDIT3, STT3A, ARG2 and
FAM129A, to distinguish follicular carcinoma from
follicular adenoma. Our intention was to optimize
the previously described methodology before estab-
lishing it in our diagnostic routine. Surprisingly,
and discordant to the results of Cerutti et al,
31 we
found, as shown in Figure 2a, the percentage of our
in-house cases with positive staining of follicular
adenoma and follicular carcinoma to be identical
Figure 4 Immunohistochemical detection of DDIT3, STT3A, ARG2 and FAM129A in separate cases of normal thyroid tissue (a–d;
 200), follicular adenoma (e–h;  200) and follicular carcinoma (i–l;  400) on tissue microarray slides. FTA¼follicular thyroid
adenoma, FTC¼follicular thyroid carcinoma.
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and STT3A), and with no significant difference
in percentage of cases of follicular adenoma and
follicular carcinoma with staining for ARG2 and
FAM129A. Furthermore, the percentage of cases
showing staining of the adjacent benign thyroid
cells was not significantly different from the
percentage of tumor cases showing staining. When
examining the tissue microarray cases (Figure 2b),
we found no significant difference in percentage
of positive follicular adenoma and follicular carci-
noma cases for three of the four antibodies examined
(STT3A, ARG2 and FAM129A), and only for DDIT3,
we did find the difference in percentage of posi-
tively stained cases of follicular adenoma and
follicular carcinoma to be of weak significance. It
is unlikely that the positive DDIT3, STT3A, ARG2
and FAM129A immunostaining of follicular adeno-
ma and normal tissues was due to differences in
methodology. We used the same antigen retrieval
and staining protocols as originally described by
Cerutti et al,
31,32 and extensively optimalized the
dilutions of the primary antibodies used. Further-
more, staining was performed using the same
commercially available antibodies against ARG2
and DDIT3 utilized by Cerutti et al,
31 and in-house
generated reagents were found to have high speci-
ficity to their cognate antigen in western blots.
However, the anti-FAM129A monoclonal antibody
performed poorly in immunohistochemistry and
western blotting, probably reflecting its low avidity.
We additionally stained multiple cores of follicu-
lar adenoma, follicular carcinoma and normal
thyroid parenchyma on commercially constructed
tissue microarray slides. The tissue microarray
results agreed with those obtained using wax
sections prepared in-house, and positive follicular
cell staining was found in cores containing normal
thyroid tissue. The P-value of 0.04 for DDIT3 was
found examining a small number of follicular
carcinoma (n¼8) and follicular adenoma (n¼21)
tissue microarray specimens. This finding does not
fit with the observations made of the in-house cases
demonstrating positive staining in all follicular
adenomas (n¼15) and all follicular carcinomas
(n¼15). Additionally, some quantitative differences
were seen when comparing staining with anti-ARG2
and anti-FAM129A polyclonal antibodies on fresh
sections with that on tissue microarray slides. These
were most probably related to variable degrees of
epitope degradation during the prolonged storage of
the commercial tissue microarrays.
34 However, as
the tissues used to construct these arrays were fixed,
embedded and sectioned by an independent labora-
tory, they provide an appropriate control for the
variables associated with paraffin block preparation
and handling.
Because of the surprising disparity between our
immunohistochemical results and those described
previously,
31,32 we determined the expression of
ARG2, FAM129A, DDIT3 and STT3A in follicular
adenoma and follicular carcinoma biopsy speci-
mens, using western blotting. In contrast to immuno-
histochemistry, western blotting can evaluate protein
expression, antibody specificity and provide a Mr of
the antibody-binding moiety and hence, a presump-
tive identity. With the exception of the commercial
anti-DDIT3 antibody, the antibody reagents demon-
strated good specificity and reacted with antigens of
the expected size in follicular adenoma and folli-
cular carcinoma lysates. In agreement with our
observations using immunohistochemistry, a sizable
proportion of the follicular adenomas displayed
significant expression of ARG2, FAM129A and
STT3A. Although anti-DDIT3 (Santa Cruz Biotech-
nology) detected a protein of the expected size in one
follicular carcinoma lysate, it displayed marked non-
specificity. In a recent paper by Haataja et al,
35 three
out of seven commercially available DDIT3 antibo-
dies (including the antibody from Santa Cruz
Biotechnology that we used) gave false results by
western blotting and immunocytochemistry. This
non-specificity may explain why we observed
positive immunohistochemical staining in all freshly
cut follicular adenoma and normal tissue sections.
Although Cerutti et al
31,32 used the same antibody,
they did not report on whether they characterized
each of their purchased batches.
Considering the urgent need for a technique that
can reliably discriminate between follicular carci-
noma and follicular adenoma, it is surprising that a
search of the literature indicates that we are the first
to attempt to replicate a method originally described
in 2004.
32 Matsumoto et al
36 observed binding of
antibodies to FAM129A to thyroid tumors with
oxyphilic cytoplasm, to oxyphilic follicular adeno-
ma and to oxyphilic variants of follicular carcinoma.
However, the authors also noted FAM129A expres-
sion in 25% of follicular non-oxyphilic follicular
adenoma and in only 50% of the non-oxyphilic
Table 1 Sensitivity and specificity of immunohistochemistry
with CI; sensitivity is defined as the proportion of follicular
carcinoma patients who expressed the marker in tumor, and
specificity as the proportion of patients with follicular adenoma,
who did not express the marker
31
Sensitivity 95% CI Specificity 95% CI
(a) In-house cases
DDIT3 1.00 — 0 —
STT3Ap 1.00 — 0 —
STT3Am 1.00 — 0 —
ARG2 0.40 0.29–0.64 0.80 0.55–0.93
FAM129Ap 0.87 0.62–0.96 0.40 0.20–0.64
FAM129Am 0.33 0.15–0.58 0.87 0.62–0.96
(b) Tissue microarray cases
DDIT3 1.00 — 0.24 0.11–0.45
STT3Ap 1.00 — 0.14 0.05–0.35
STT3Am 1.00 — 0.19 0.08–0.40
ARG2 0.12 0.02–0.47 0.90 0.71–0.97
FAM129Ap 1.00 — 0.19 0.08–0.40
Abbreviation: CI, confidence intervals.
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also suggest that FAM129A expression discrimi-
nates poorly between follicular carcinoma and
follicular adenoma. In a recent reverse-transcription
PCR study by Patel et al
37 on fine-needle aspiration
biopsy specimens, a marked downregulation of
FAM129A was found in follicular carcinoma, folli-
cular variant of papillary thyroid carcinoma and
oxyphilic follicular carcinomas, compared with
matched-normal tissue. The findings by Matsumoto
et al
36 and Patel et al
37 are discordant to those
presented by Cerutti et al
38 in a recent validation
study, which confirmed their previous findings of
overexpression of FAM129A in all follicular carci-
nomas. Bryson et al
39 found significant differences
in DDIT3 expression in a tissue panel comprising
62 follicular adenomas and 62 follicular carci-
nomas. However, they determined a sensitivity of
82% with a specificity of only 21%, which is in
agreement with our results. A study by Netea-Maier
et al
40 using different gel electrophoresis found no
variance in the abundance of ARG2, FAM129A,
DDIT3 and STT3A between follicular carcinoma and
follicular adenoma. The authors concluded that the
differences in mRNA levels between follicular
carcinoma and follicular adenoma as reported by
Cerutti et al
32 are of limited value, because mRNA
expression frequently does not reflect protein
abundance. Similarly, a study performing global
gene expression analysis of follicular thyroid tumors
found no difference in ARG2, DDIT3 and STT3A
expression between follicular adenoma and follicu-
lar carcinoma.
41 In a meta-analysis and meta-review
by Griffith et al
42 on 21 published thyroid cancer
Figure 5 Determination of ARG2, FAM129A, DDIT3 and STT3A tissue expression by western blotting. Lysates prepared from follicular
carcinoma (lane 1, 2), normal thyroid parenchyma (lane 3, 4) and follicular adenoma (lane 5–9) tissue were subjected to western blotting
as described in the legend to Figure 1. Normal tissues 2 and 3 were obtained from the uninvolved thyroid lobe of patent 2 and 5,
respectively. *Sample not run due to insufficient lysate.
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Cerutti et al,
32 ARG2, DDIT3, STT3A and FAM129A
are not among the 39 markers with overlap of three
or more candidate markers for the cancer versus
non-cancer group.
Our insight into gene expression in tumor cells
has increased rapidly with the help of DNA and
protein microarray analyses. However, the interpre-
tation of the acquired data is challenging, and is
subject to several potential pitfalls. The importance
of a close collaboration between the investigators
performing the microarrays and experienced biosta-
tisticians is crucial.
43 Morphology is still the gold
standard when evaluating thyroid neoplasms.
Indeed, for the majority of thyroid tumors, the
identification of ‘‘abnormal’’ tissue on histological
preparations will probably long remain a prerequi-
site before performing immunohistochemistry or
molecular analysis. Unfortunately, as this study
demonstrates, the search for the ideal marker
capable of discriminating between follicular carci-
noma and follicular adenoma must continue.
In conclusion, in this study, we determined
whether screening for the expression of the biomar-
kers DDIT3, STT3A, ARG2 and FAM129A, is able to
distinguish between follicular thyroid adenoma and
carcinoma. Regrettably, using both immunohisto-
chemistry and western blotting, we demonstrate that
these markers are not useful for this purpose. The
reasons for the discordance between our results and
those of Cerutti et al
31,32 are, at present, and despite
considerable focus on quality assurance of all steps,
unknown. In our hands, the method is not usable for
screening thyroid nodules in patient populations.
The failure of this study to replicate a previously
published method highlights the need for extensive
validation studies to determine if a previously
advanced classifier has clinical utility in an inde-
pendent set of cases.
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